What are the similar drugs to Sotatercept-Winrevair?

Sotatercept-Winrevair is a first-in-class drug in the "activin/inhibin signaling modulation" category. This mechanism is relatively new in the field of pulmonary arterial hypertension (PAH). Therefore, in a strict sense, there are few or no "similar" drugs that are currently approved and widely used.

Traditionally,PAH drug spectrum includes endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs, and soluble guanylyl cyclase (sGC) stimulators. These drugs mainly improve pulmonary vasomotion, inhibit platelet aggregation, or improve vascular remodeling. They belong to different but complementary treatment categories with different action pathways. Common representative drugs include bosentan/ambrisentan (endothelin receptor antagonists), sildenafil/tadalafil (PDE5 inhibitors), treprostinil/epoprostenol (prostaglandins), and riociguat (sGC stimulator). These drugs remain the basis of treatment for most patients, and soltercept is often used as an add-on option to these standard drugs.

At the R&D pipeline level, other molecules surrounding the TGF-β/BMP signaling pathway and vascular remodeling are also being explored, including strategies to repair or regulate the BMPR2 downstream pathway, as well as biological agents and small molecules targeting inflammation, metabolism or cell proliferation pathways. Some early/mid-stage studies are testing molecules with similar concepts, but until large-scale phase III evidence is obtained and approved, sotercept is still the first representative of this type of strategy to enter clinical routine. In clinical practice, R&D progress and long-term safety data will gradually affect the design of drug combinations and treatment sequences in this field.

Generally speaking, Soltercept has opened up a window for the transformation of PAH treatment from vasodilation to vascular remodeling regulation, and may be combined with more drugs targeting pathological remodeling in the future to provide new treatment logic for refractory or progressive patients.

Reference materials:https://www.drugs.com/mtm/sotatercept.html